Physician profile
Michael W Shaffer
NPI 1811154909
$2,118.29
in general payments reported to CMS, 2019-2025
30 companies · $593 in 2025
The $593 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $71.74 · 2021: $15.92 · 2022: $148 · 2023: $525 · 2024: $559 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,664 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,663.76 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $396.84 | 2022-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $362.21 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $208.01 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $152.21 | 2019-2025 | Evenity, Prolia, Otezla |
| Abbott Laboratories | $129.16 | 2022-2025 | Freestyle Libre 3 |
| Pfizer INC. | $117.99 | 2020-2025 | |
| Exact Sciences Corporation | $76.64 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $72.42 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $72.11 | 2019-2025 | Gardasil 9, Capvaxive, Dificid |
| Astrazeneca Pharmaceuticals LP | $64.95 | 2023-2025 | Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $61.57 | 2019-2024 | Spravato, Xarelto |
| Sanofi-Aventis U.S. LLC | $43.62 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $41.50 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.80 | 2023-2024 | Xifaxan |
| Inspire Medical Systems, INC. | $26.42 | 2024 | Inspire |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $24.65 | 2023 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $22.56 | 2025 | Rexulti |
| Corcept Therapeutics | $20.77 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $19.79 | 2019 | |
| Mannkind Corporation | $18.87 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $18.32 | 2024 | Crysvita |
| Tactile Systems Technology INC | $18.14 | 2024 | Entre Plus, Flexitouch Plus |
| Phathom Pharmaceuticals, INC. | $16.42 | 2024 | Voquezna |
| Currax Pharmaceuticals LLC | $16.38 | 2024 | Contrave |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.62 | 2023 | Jardiance, Tradjenta |
| Novartis Pharmaceuticals Corporation | $14.47 | 2019 | |
| Noven Therapeutics, LLC | $14.30 | 2024 | Xelstrym |
| Allergan, INC. | $13.74 | 2019 | |
| Amarin Pharma, INC. | $12.82 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Shaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.